Compare STKS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | XLO |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 56.9M |
| IPO Year | 2011 | 2021 |
| Metric | STKS | XLO |
|---|---|---|
| Price | $1.59 | $8.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.70 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 16.1K | 9.5K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,722,000.00 | $43,766,000.00 |
| Revenue This Year | $7.47 | N/A |
| Revenue Next Year | $8.12 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 19.66 | ★ 589.88 |
| 52 Week Low | $1.62 | $0.46 |
| 52 Week High | $3.38 | $9.90 |
| Indicator | STKS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 36.52 | 48.51 |
| Support Level | N/A | $8.52 |
| Resistance Level | $2.00 | $9.15 |
| Average True Range (ATR) | 0.04 | 0.29 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 38.89 | 57.33 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.